Trial Profile

A phase 3 study of AB521 in kidney cancer

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 24 Feb 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Casdatifan (Primary) ; Protein tyrosine kinase inhibitors
Indications Renal cancer; Renal cell carcinoma
Focus Adverse reactions; Therapeutic Use

Most Recent Events

21 Feb 2024 According to an Arcus Biosciences media release, the company plans to initiate a Phase 3 combination study in Renal Carcinoma in early 2025.
31 Jan 2024 New trial record
29 Jan 2024 According to an Arcus Biosciences media release, additional investment by Gilead which extends cash runway into 2027, will enable the company to funs the phase 3 study in pancreatic cancer.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com